$SNDL Inc (SNDL.US)$
notice the steps in ask orders ? those arent natural ask prices but instead artificial resistances. hedges place these “walls” to prevent the price from climbing. each wall needs be sold before going on to the next price point. notice how the bid chart is smooth ?

$Pubmatic (PUBM.US)$
the chart look like this

$Vir Biotechnology (VIR.US)$ climbed after it said it has more data showing that its COVID-19 anti-body therapy is effective against Omicron variant. The company said sotrovimab has also been designed to achieve high concentration in the lungs to ensure optimal penetration into airway tissues affected by the virus and to have an extended half-life.

$TriState Capital (TSC.US)$ Will buying this make a profit?

A short squeeze can occur when a heavily shorted stock rises in value instead of falling. Short sellers could be looking to close out their position and can face a loss if they have to buy back the shares they initially borrowed at a higher price.
Here is a look at Fintel's top five short squeeze candidates for the week of Dec. 13.
Men's health pharmaceutical company  $Petros Pharmaceuticals (PTPI.US)$ tops the Fintel leaderboard for the week. The stock has 25.4% of its float short with short interest up 459% in recent weeks, according to Fintel. Short interest is up 2,470% in the last month on shares of PTPI. Fintel shows a cost to borrow of 254%, which is one of the highest on record.
Life sciences company $iSpecimen (ISPC.US)$ comes in second place on the Fintel leaderboard for the week. The company has 19.7% of its public float shorted. Short interest is up over 4,400% in ISPC shares from the prior report. Fintel points out that institutional ownership is down in ISPC shares in the recent quarter. Insiders have been buying shares consistently over the last few weeks. The cost to borrow on ISPC shares is 175%, which Fintel said would normally top the list if not for the high number assigned to PTPI shares.
Biotechnology company  $Longeveron (LGVN.US)$ ranks third on this week's list. Fintel shows 30.5% of the company's public float short. Short interest of 1.2 million shares is up 477% in the last month, according to the report. LGVN has a high cost to borrow of 152%.
Biopharmaceutical company  $Vallon Pharmaceuticals (VLON.US)$ has 22.8% of its float short. Short interest has risen 855% from previous reports, according to Fintel. The cost to borrow on VLON shares is 62.1%. Fintel highlighted that institutional shares have declined over 30% in the most recent quarter.
Material handling industry company  $Greenland Technologies (GTEC.US)$ joins the short squeeze leaderboard in fifth place. Short interest in GTEC is up over 1,500% from the previous report. The cost to borrow on GTEC shares is 41%.
Mooers, let's look for the next  $GameStop (GME.US)$ or  $AMC Entertainment (AMC.US)$.
Source: Benzinga, Fintel